# Arvinas to Present at Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference
Ticker: ARVN
Company: Arvinas, Inc.
Source: Arvinas, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.arvinas.com
## Summary

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare

## Article Body
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare
## Recent Company News
- 2026-06-25 13:46 EST — [Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease](https://biopharmsignal.com/news/ARVN/arvinas-joins-the-michael-j-fox-foundation-s-lite-and-ppmi-programs-to-advance-new-therapies-targeting-lrrk2-for-parkinson-s-disease) — Source: Arvinas, Inc.
- 2026-06-25 13:46 EST — [Arvinas to Present at Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference) — Source: Arvinas, Inc.
- 2026-06-25 13:46 EST — [Arvinas Employees Give Back During Company-wide Impact Day](https://biopharmsignal.com/news/ARVN/arvinas-employees-give-back-during-company-wide-impact-day) — Source: Arvinas, Inc.
- 2026-06-25 13:46 EST — [Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)](https://biopharmsignal.com/news/ARVN/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant) — Source: Arvinas, Inc.
- 2026-06-25 13:46 EST — [Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arvinas, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)